SK Biopharmaceuticals (KRX:326030) won a pharmaceutical supply agreement from subsidiary SK Life Science, according to a Wednesday filing with the Korea Exchange.
The contract, valued at 63.3 billion won, is valid till Sept. 25.
Shares of SK Biopharmaceuticals fell more than 1% at market close.